Eijin Ashikaga, Hirokazu Honda, Hiroki Suzuki, Nozomu Hosaka, Yuki Hirai, Daisuke Sanada, Mari Nakamura, Hisako Nagai, Kei Matsumoto, Noriyuki Kato, Masanori Mukai, Makoto Watanabe, Keiko Takahashi, Kanji Shishido, Tadao Akizawa
Levels of fibroblast growth factor (FGF) 23, a phosphatonin, are frequently elevated in patients with end-stage renal disease (ESRD) who are on maintenance hemodialysis (MHD). However, the role of FGF23 remains unclear because renal FGF receptor function might be impaired. The present cross-sectional study examines a cohort of patients (n = 196) on MHD who were not undergoing therapy with lipid-lowering drugs including sevelamer. Non-fasting venous blood samples were withdrawn before the hemodialysis (HD) session on the third day after the previous HD session to measure serum levels of albumin, calcium (Ca), phosphate (P), alkaline phosphatase, intact parathyroid hormone (PTH), total cholesterol (C), high-density lipoprotein (HDL)-C, low-density lipoprotein(LDL)-C, oxidative LDL-C, high-sensitivity C-reactive protein (HsCRP), interleukin-6 (IL-6), and FGF23...
June 2010: Therapeutic Apheresis and Dialysis